The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2022

Filed:

Aug. 28, 2018
Applicant:

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Caroline Chopko Ahrens, Kennett Square, PA (US);

Linda G. Griffith, Cambridge, MA (US);

Steven Robert Tannenbaum, Brookline, MA (US);

Christi Dionne Cook, Cambridge, MA (US);

Ravindra Kodihalli, Acton, MA (US);

Douglas A. Lauffenburger, Cambridge, MA (US);

Evan L. Chiswick, Jamaica Plain, MA (US);

Miles Miller, Cambridge, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/573 (2006.01); G01N 33/535 (2006.01); G01N 33/58 (2006.01); G01N 33/543 (2006.01); G01N 33/533 (2006.01); C12Q 1/37 (2006.01); G01N 33/574 (2006.01); G16B 99/00 (2019.01); G16C 99/00 (2019.01);
U.S. Cl.
CPC ...
G01N 33/573 (2013.01); C12Q 1/37 (2013.01); G01N 33/533 (2013.01); G01N 33/535 (2013.01); G01N 33/54306 (2013.01); G01N 33/54313 (2013.01); G01N 33/54326 (2013.01); G01N 33/58 (2013.01); C12Y 304/24007 (2013.01); C12Y 304/24024 (2013.01); C12Y 304/24035 (2013.01); G01N 33/574 (2013.01); G16B 99/00 (2019.02); G16C 99/00 (2019.02);
Abstract

Proteases regulate a wide range of normal cellular functions where dysregulated activity is observed in various diseases. Compositions and methods use protease activity multiplexed bead-based immunoassays to profile protease activity. This platform technology integrates protease activity measurements with total protein quantification techniques. It represents a significant improvement over existing detection techniques by allowing for multiplexed, sensitive active protease measurements in complex biological samples. Exemplary multiplexed detections are realized in a single assay using a minute sample amount (e.g., 5 μl) for active recombinant MMP-1, -2, -3, -7, 9, and 12 and those same MMPs in cell culture supernatant, menstrual fluid effluent, and peritoneal aspirates. This multiplexed platform achieves high level of sensitivities equal to or better than existing leading single-plex detection strategies. It also allows for high throughput screening to identify inhibitors of proteases in complex, donor-derived samples.


Find Patent Forward Citations

Loading…